Moderna surges 177% as cancer vaccine hype outruns the math

Moderna surged 177% to $174.38 on Aug. 19, its largest single-day gain for an S&P 500 company in more than two decades, after a Phase 3 melanoma trial for its personalized mRNA vaccine met its primary and key secondary endpoints.

"The market is pricing in the possibility that the vaccine could become something like the next Keytruda or Opdivo," said Luca Issi, an analyst at RBC Capital Markets. "But the vaccine could instead prove effective in a much narrower set of tumors."

The rally lifted Moderna's market value to about $60 billion from roughly $25 billion before the announcement. Merck and BioNTech joined the move, adding about $80 billion in combined market capitalization in days: BioNTech closed up 22% at $113.12, Pfizer gained 3.7%, and the Nasdaq biotech index set a record, up 4.4%. Volume hit 185.1 million shares, about 19 times the three-month average.

The financial math is sobering. Daina Graybosch, an analyst at Leerink Partners, models the therapy generating low-single-digit billions in annual sales by 2032. Even in a bull case where the vaccine peaks at $10 billion in annual sales for the partnership, that could support roughly $40 billion in added value for the two companies combined — less than the market added in a single afternoon.

Why Melanoma Is the Exception, Not the Rule

The key reason for the skepticism is that success in melanoma is far from proof the approach will work elsewhere. Every tumor is different, and melanoma is unusually well-suited for this therapy. The vaccine analyzes a patient's tumor, selects up to 34 mutations as targets and trains the immune system to recognize them, yet typically only two or three generate a meaningful immune response, Graybosch explained. In melanoma, the abundance of mutations gives the vaccine more targets to work with, while the tumor's relative sensitivity to immunotherapy gives those targets a better chance of producing an immune response.

The cancers Merck and Moderna are pursuing next are less forgiving. Kidney cancer has fewer mutations to target, while bladder cancer has a more suppressive tumor environment. Some of the hardest tumors, such as pancreatic cancer, are notoriously resistant to immune-based treatments.

A $300,000 Dose With Slimmer Margins

Then there are the drug's economics. Traditional drugs are made in bulk. This vaccine is different: a surgeon removes the tumor and sends it to a lab, where its mutations are sequenced and an algorithm identifies the targets for a personalized mRNA vaccine. Like other personalized therapies, it is a vastly more expensive way to manufacture a drug.

The companies haven't said what they will charge, but based on comparable therapies the full treatment could cost in the ballpark of $300,000. Higher prices run into aggressive negotiations in Europe, and the companies may have less room to charge American patients more as the Trump administration pushes policies that tie U.S. drug prices more closely to those paid in other wealthy countries. The result could be substantially lower margins than the 90%-plus of conventional drugs — at least initially, gross margins could land between 50% and 80%, Graybosch said.

Analysts Split on What One Trial Is Worth

The analyst scramble after Aug. 19 was revealing. Morgan Stanley raised its target to $89 from $39, Goldman Sachs went to $120 from $67, and BofA upgraded Moderna to Neutral from Underperform with a $170 target. Jefferies also set a $170 target, citing potential global peak sales of roughly $54 billion for the personalized oncology platform. Yet the stock closed at $174.38 — above every new target except the most bullish, and 31% above Goldman's.

Moderna ended the second quarter with $6.9 billion in cash and investments, though it spent $950 million in July on a litigation settlement and guided to $4.7 billion to $5.2 billion by year-end. The company posted a net loss of $782 million in the quarter. Full results from INTerpath-001 are due at the ESMO conference in Madrid at the end of October, and readouts in kidney, bladder and lung cancer are expected in late 2026 and 2027.

The bigger promise of mRNA may be using it to prevent cancer in people at high risk, before the disease takes hold — a vaccine in the truest sense. That frontier is nowhere close. For now, this week's excitement is likely to run into the cold realities of tumors and economics.

This article is for informational purposes only and does not constitute investment advice.